Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ:IBRX) with a Neutral and raises the price target from $5 to $6.
Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $6
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.